AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21118395 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (10 mg once daily) plus mosapride citrate (5 mg three times a day)
Number of subjects: 200
Study 21118395 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole plus placebo
Number of subjects: 200
Study 20031745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of supersaturated oxygen (SSO(2)) for 90 minutes
Number of subjects: 301
Study 20031745 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301
Study 20031745 — intervention group
Group type: EXPERIMENTAL
Intervention: SSO(2)
Number of subjects: 301
Study 19391529 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point taping and pressing therapy
Number of subjects: 180
Study 19391529 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine (30 mg, thrice daily)
Number of subjects: 180
Study 15844061 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative temperature measurement > or = 38.0 degrees C
Number of subjects: 284
Study 15844061 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative temperature measurement < 38 degrees C
Number of subjects: 284
Study 12383535 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg) orally every hour for a maximum of three doses
Number of subjects: 237
Study 12383535 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally every hour for a maximum of three doses
Number of subjects: 237
Study 12383535 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 237
Study 12383535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 9819040 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at 70 microg/kg dosage
Number of subjects: 0
Study 9819040 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at 35 microg/kg dosage
Number of subjects: 0
Study 9819040 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) in home treatment study
Number of subjects: 0
Study 9819040 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) in compassionate use study
Number of subjects: 0
Study 7699549 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of nebulized ipratropium bromide (250 micrograms/dose)
Number of subjects: 120
Study 7699549 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of nebulized ipratropium bromide
Number of subjects: 120
Study 7699549 — intervention group
Group type: COMPARATOR
Intervention: No ipratropium (Control Group)
Number of subjects: 120
Study 2539929 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentanoic acid (EPA) 10 g per day
Number of subjects: 37
Study 2539929 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 37
Study 899864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound method for detection of DVT
Number of subjects: 47
Study 899864 — intervention group
Group type: COMPARATOR
Intervention: Clinical evaluation
Number of subjects: 47
Study 11770273 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep fluid-based cytology
Number of subjects: 5428
Study 28658076 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 m front crawl
Number of subjects: 10
Study 28658076 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 m front crawl
Number of subjects: 10
Study 28658076 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 m front crawl
Number of subjects: 10
Study 29976746 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 339
Study 29976746 — intervention group
Group type: COMPARATOR
Intervention: Control (no everolimus)
Number of subjects: 339
Study 27018531 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual PCIT
Number of subjects: 81
Study 27018531 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PCIT
Number of subjects: 81
Study 25369200 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 µg of misoprostol sublingually
Number of subjects: 1140
Study 25369200 — intervention group
Group type: COMPARATOR
Intervention: 10 IU of oxytocin intramuscularly
Number of subjects: 1140
Study 21953471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 100 mg monthly
Number of subjects: 698
Study 21953471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg monthly
Number of subjects: 698
Study 21953471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (100 mg and 150 mg monthly)
Number of subjects: 698
Study 21526669 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DLS)
Number of subjects: 50
Study 21526669 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic Bronchoscopy (FOB)
Number of subjects: 50
Study 17589341 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 50
Study 17589341 — intervention group
Group type: COMPARATOR
Intervention: Mini-incision open donor nephrectomy (ODN)
Number of subjects: 50
Study 16222027 — intervention group
Group type: EXPERIMENTAL
Intervention: Household-based ceramic water filters
Number of subjects: 0
Study 16222027 — intervention group
Group type: COMPARATOR
Intervention: Control group (no filters)
Number of subjects: 0
Study 12038644 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) exposure
Number of subjects: 33
Study 12038644 — intervention group
Group type: COMPARATOR
Intervention: Exposure in vivo
Number of subjects: 33
Study 10664928 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 16 mg
Number of subjects: 40
Study 10664928 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 40
Study 10664928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg and 20 mg
Number of subjects: 40
Study 10664928 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine 120 mg
Number of subjects: 40
Study 7888428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ademetionin (therapy group)
Number of subjects: 21
Study 7888428 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 21
Study 2203518 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete androgen blockade (addition of a pure antiandrogen to castration)
Number of subjects: 0
Study 2203518 — intervention group
Group type: COMPARATOR
Intervention: Castration
Number of subjects: 0
Study 70639 — intervention group
Group type: EXPERIMENTAL
Intervention: High wheat-fibre regimen
Number of subjects: 26
Study 70639 — intervention group
Group type: COMPARATOR
Intervention: Low wheat-fibre regimen
Number of subjects: 26
Study 31740727 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 46
Study 31740727 — intervention group
Group type: COMPARATOR
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 46
Study 29875218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (FNG)
Number of subjects: 550
Study 29875218 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 550
Study 29875218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (FNG) in treatment-naive patients
Number of subjects: 550
Study 29875218 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl fumarate (DMF) in treatment-naive patients
Number of subjects: 550
Study 29875218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (FNG) in switchers
Number of subjects: 550
Study 29875218 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl fumarate (DMF) in switchers
Number of subjects: 550
Study 26817510 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video gaming
Number of subjects: 22
Study 26817510 — intervention group
Group type: COMPARATOR
Intervention: Seated video gaming
Number of subjects: 22
Study 24656435 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Voiding Programme (SVP)
Number of subjects: 43
Study 23021113 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (Quick 2.0 and Smart Clip) with superelastic or thermoactive archwires
Number of subjects: 40
Study 23021113 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (1.1, 1.3, 1.5)
Number of subjects: 40
Study 21053384 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based recruitment
Number of subjects: 189
Study 21053384 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty-based recruitment
Number of subjects: 189
Study 21053384 — intervention group
Group type: COMPARATOR
Intervention: Both recruitment settings
Number of subjects: 189
Study 17438965 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of ICBN
Number of subjects: 126
Study 17438965 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection (Control)
Number of subjects: 126
Study 17438965 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of LTV
Number of subjects: 126
Study 17438965 — intervention group
Group type: COMPARATOR
Intervention: Control (No preservation of LTV)
Number of subjects: 126
Study 15883121 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training
Number of subjects: 18
Study 15883121 — intervention group
Group type: COMPARATOR
Intervention: Single-task training
Number of subjects: 18
Study 15883121 — intervention group
Group type: COMPARATOR
Intervention: No-training
Number of subjects: 18
Study 11852377 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucotrend Premium monitor (Group B)
Number of subjects: 179
Study 11852377 — intervention group
Group type: EXPERIMENTAL
Intervention: One Touch Profile monitor (Group C)
Number of subjects: 179
Study 11852377 — intervention group
Group type: COMPARATOR
Intervention: Previous system (Group A)
Number of subjects: 179
Study 9134079 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy (1 hour per week)
Number of subjects: 67
Study 9134079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group therapy (3 hours, 3 times weekly)
Number of subjects: 67
Study 9134079 — intervention group
Group type: COMPARATOR
Intervention: Randomly assigned to individual therapy
Number of subjects: 67
Study 9134079 — intervention group
Group type: COMPARATOR
Intervention: Randomly assigned to intensive group therapy
Number of subjects: 67
Study 7892014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 30 mg
Number of subjects: 0
Study 7892014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 45 mg
Number of subjects: 0
Study 7892014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 15 mg
Number of subjects: 0
Study 7892014 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 2831814 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2b interferon at 2.5 x 10(6) IU per day
Number of subjects: 1200
Study 2831814 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2b interferon at 1.7 x 10(6) IU per day
Number of subjects: 1200
Study 2831814 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2b interferon at 3.0 x 10(6) IU per day (previous year)
Number of subjects: 1200
Study 2831814 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 1200
Study 2831814 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily use of interferon
Number of subjects: 1200
Study 2831814 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose of interferon
Number of subjects: 1200
Study 31549770 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose-rate brachytherapy
Number of subjects: 43000
Study 30939090 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Number of subjects: 491
Study 30939090 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 491
Study 29183525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension group (refractory hypotension without hyperlactatemia)
Number of subjects: 1588
Study 29183525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlactatemia group (hyperlactatemia without refractory hypotension)
Number of subjects: 1588
Study 29183525 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical group (both refractory hypotension and hyperlactatemia)
Number of subjects: 1588
Study 29183525 — intervention group
Group type: COMPARATOR
Intervention: Comparison among the three groups
Number of subjects: 1588
Study 29183525 — intervention group
Group type: COMPARATOR
Intervention: Comparison between hyperlactatemia group and typical group
Number of subjects: 1588
Study 25179265 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief sexual risk reduction intervention
Number of subjects: 617
Study 25179265 — intervention group
Group type: COMPARATOR
Intervention: Education-only control condition
Number of subjects: 617
Study 22725836 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoid/piperine treatment (4 g curcuminoids plus 24 mg piperine)
Number of subjects: 8
Study 22725836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 21631380 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss plus exercise program (6-month duration)
Number of subjects: 0
Study 18155179 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-compatible flanker of a non-target color at varying distances from the target.
Number of subjects: 0
Study 18155179 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-incompatible flanker of a non-target color at varying distances from the target.
Number of subjects: 0
Study 18155179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cued target location and higher salience target than flanker.
Number of subjects: 0
Study 16407967 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia via selective head cooling for 72 hours
Number of subjects: 58
Study 16407967 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 58
Study 16407967 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia via selective head cooling
Number of subjects: 58
Study 12616587 — intervention group
Group type: EXPERIMENTAL
Intervention: Latino and Native American participants
Number of subjects: 9069
Study 12616587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic minority subjects with self‐acknowledged eating and weight concerns
Number of subjects: 9069
Study 12616587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic minority subjects
Number of subjects: 9069
Study 10849033 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (migraine for 2 years or less)
Number of subjects: 49
Study 10849033 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (migraine for 10 years or more)
Number of subjects: 49
Study 10849033 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 healthy subjects)
Number of subjects: 49
Study 9407253 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drinks (CHO)
Number of subjects: 16
Study 9407253 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks (P)
Number of subjects: 16
Study 7957538 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fosinopril daily for 16 weeks
Number of subjects: 50
Study 7957538 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks followed by 50 mg atenolol daily for 12 weeks
Number of subjects: 50
Study 7957538 — intervention group
Group type: COMPARATOR
Intervention: Placebo wash-out period of 2-6 weeks prior to treatment
Number of subjects: 50
Study 2954969 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely (with bisacodyl)
Number of subjects: 107
Study 2954969 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 107
Study 29288309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (0.2 mg/kg bolus, 120 μg/kg/h continuous infusion)
Number of subjects: 58
Study 29288309 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 58
Study 26705744 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive training program
Number of subjects: 86
Study 26705744 — intervention group
Group type: COMPARATOR
Intervention: Comparison training program
Number of subjects: 86
Study 25017612 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus + Exemestane
Number of subjects: 0
Study 25017612 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Exemestane
Number of subjects: 0
Study 22248223 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% clarithromycin gel (CLM)
Number of subjects: 61
Study 22248223 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 61
Study 20957329 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment (problem-solving)
Number of subjects: 0
Study 20957329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18275619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MUFA-rich)
Number of subjects: 20
Study 16864148 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA (2 mg E2 plus 1 mg NETA)
Number of subjects: 43
Study 16864148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9562935 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis or primary coronary angioplasty
Number of subjects: 272
Study 9562935 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting left ventricular ejection fraction
Number of subjects: 272
Study 9562935 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing eligibility
Number of subjects: 272
Study 9562935 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score from exercise test variables
Number of subjects: 272
Study 9562935 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide ventriculography
Number of subjects: 272
Study 7650224 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-mg famotidine wafer
Number of subjects: 450
Study 7650224 — intervention group
Group type: COMPARATOR
Intervention: 20-mg and 40-mg famotidine wafers
Number of subjects: 450
Study 2468734 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (8 mg/kg/day)
Number of subjects: 19
Study 2468734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 137410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 11
Study 6972294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2, 0.5 mg administered 15 min before aspirin
Number of subjects: 0
Study 6972294 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, 600 mg four times daily
Number of subjects: 0
Study 6972294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2, 0.5 mg four times daily
Number of subjects: 0
Study 30784641 — intervention group
Group type: EXPERIMENTAL
Intervention: Major stroke
Number of subjects: 3763
Study 30784641 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 3 acute kidney injury
Number of subjects: 3763
Study 30784641 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe paravalvular leak (PVL)
Number of subjects: 3763
Study 30784641 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-threatening bleeding
Number of subjects: 3763
Study 30784641 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 3763
Study 30784641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild paravalvular leak (PVL)
Number of subjects: 3763
Study 30784641 — intervention group
Group type: EXPERIMENTAL
Intervention: New pacemaker implantation
Number of subjects: 3763
Study 30784641 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor stroke
Number of subjects: 3763
Study 30784641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular injury
Number of subjects: 3763
Study 29371008 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based program promoting outdoor activities (up to 11 hours weekly)
Number of subjects: 693
Study 29371008 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based program promoting outdoor activities (≥200 minutes outdoors)
Number of subjects: 693
Study 26507428 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexanide
Number of subjects: 146
Study 26507428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 26507428 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexanide (PP analysis)
Number of subjects: 146
Study 26507428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PP analysis)
Number of subjects: 146
Study 24618499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic Dexamethasone (ITD)
Number of subjects: 26
Study 24618499 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 26
Study 22020318 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 800 mg/day
Number of subjects: 43
Study 22020318 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 1400 mg/day
Number of subjects: 43
Study 22020318 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV (combined with vorinostat)
Number of subjects: 43
Study 19194050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 19194050 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg exenatide
Number of subjects: 153
Study 19194050 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg exenatide
Number of subjects: 153
Study 19194050 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg exenatide
Number of subjects: 153
Study 16712781 — intervention group
Group type: EXPERIMENTAL
Intervention: schema focused therapy or transference focused psychotherapy
Number of subjects: 50
Study 15238062 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.82 g/kg)
Number of subjects: 54
Study 15238062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11956511 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (C(max) > 7 microg/ml)
Number of subjects: 20
Study 11956511 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (C(max) < 7 microg/ml)
Number of subjects: 20
Study 9822864 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater than normal expression of platelet P-selectin (33.7 +/- 1.1)
Number of subjects: 23
Study 9822864 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater than normal expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) (57.1 +/- 2.3)
Number of subjects: 23